XS Innovations
Transforming vascular access care by addressing the root cause of failure: Persistent high and turbulent blood flow
A lifeline for Patients with End-Stage Kidney Disease
In 2020, ~3.8 million people worldwide suffered from end-stage kidney disease (ESKD)—a condition that requires life-saving treatment to replace lost kidney function and prevent fatal toxin buildup. Due to a severe shortage of kidney donors, dialysis remains the only option for nearly 80% of ESKD patients.
However, dialysis requires a high-flow vascular access site, which often leads to serious complications, affecting patients’ health and quality of life. XS Innovations has developed a breakthrough solution to minimize these complications, ensuring safer, more effective dialysis access.
With the number of ESKD patients projected to reach 5.4 million by 2030, the need for reliable, complication-free vascular access has never been more urgent. This rise is driven by increased treatment availability, lifestyle-related risk factors, and an aging global population. At XS Innovations, we are committed to transforming dialysis access, empowering patients to live better, healthier lives.
XS Innovations is set to develop the first, patented implantable valve that opens the artery-vein connection (AVF) only during dialysis, thereby addressing the root cause of complications: Persistent high and turbulent blood flow
Show video
Reducing complications, improving quality of life
Avoiding continuous high blood flow removes the root cause of multiple, serious complications and the need for frequent follow-up surgery
Improved vascular access patency
Improved cardiac function
Decreased chances of steal syndrome
Decreased chances of aneurysms
Reduced compression time and bleeding risk
